title: Proteomic approaches for studying chemoresistance in cancer.
abstract: The role of various proteins involved in drug resistance in tumor cells is discussed in this review. Two types of studies are covered: those performed in the preproteomics era and those carried out with modern proteomic tools, namely 2D (electrophoretic) maps and 2D chromatography. In the preproteomic studies, one protein had generally been held responsible for a given chemoresistance. However, analysis via proteomic tools may reveal entire sets of proteins that are up- or downregulated (or switched on/off) in chemoresistant tumor cell lines compared with parental tumor lines. Therefore, it appears more realistic to expect that exposure of cells to drugs results in the activation of different mechanisms of resistance. Such investigations have led to the broadly shared opinion that exposure of cells to drugs results in the activation of different mechanisms of resistance, and that a specific drug-resistant phenotype consists of several molecular mechanisms that are simultaneously active. The proteomic papers reviewed clearly support the hypothesis that many metabolic pathways are affected during the resistance process. Although the modulation of expression levels of such proteins is not clear proof of their role in drug resistance per se, at least some of the themes are very likely to be involved in the resistance phenotype, and thus may be potential targets for new drugs. It is hoped that this review will bring new insight in this field and will stimulate novel and deeper searches with proteomic tools (including prefractionation of subcellular organelles, such as nuclei, to bring to the fore low-abundance proteins that might be responsible for the onset of drug resistance).
authors.affiliation: University of Verona, Department of Industrial & Agricultural Biotechnologies, Laboratory of Proteome Science, Strada Le Grazie 15, Verona, Italy. righetti@sci.univr.it
authors.forename: Pier Giorgio
authors.initials: PG
authors.lastname: Righetti
authors.forename: Annalisa
authors.initials: A
authors.lastname: Castagna
authors.forename: Paolo
authors.initials: P
authors.lastname: Antonioli
authors.forename: Daniela
authors.initials: D
authors.lastname: Cecconi
authors.forename: Natascia
authors.initials: N
authors.lastname: Campostrini
authors.forename: Sabina Carla
authors.initials: SC
authors.lastname: Righetti
mesh_terms: D018528:ATP-Binding Cassette Transporters / Q000502:physiology; D000818:Animals; D017209:Apoptosis / Q000502:physiology; D014408:Biomarkers, Tumor / Q000097:blood; D019008:Drug Resistance, Neoplasm; D015180:Electrophoresis, Gel, Two-Dimensional; D018841:HSP90 Heat-Shock Proteins / Q000502:physiology; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000503:physiopathology*; D046988:Proteasome Endopeptidase Complex / Q000502:physiology; D040901:Proteomics; D051057:Proto-Oncogene Proteins c-akt / Q000502:physiology
chemical_list: D018528:ATP-Binding Cassette Transporters; D014408:Biomarkers, Tumor; D018841:HSP90 Heat-Shock Proteins; D051057:Proto-Oncogene Proteins c-akt; D046988:Proteasome Endopeptidase Complex